Therapeutic Response

CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Doxorubicin, Etoposide, Prednisolone, Rituximab, and Vincristine in patients with Non-Hodgkin Lymphoma.

Statements

Source and description

Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab S/C in combination with cyclophosphamide, doxorubicin, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's Lymphoma.